Literature DB >> 7621855

Commentary on interactions between 6-mercaptopurine therapy and thiopurine-methyl-transferase (TPMT) activity.

H L McLeod.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7621855     DOI: 10.1007/bf00202180

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  8 in total

Review 1.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients.

Authors:  P R Chocair; J A Duley; H A Simmonds; J S Cameron
Journal:  Transplantation       Date:  1992-05       Impact factor: 4.939

3.  Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance?

Authors:  H A Davies; L Lennard; J S Lilleyman
Journal:  BMJ       Date:  1993-05-08

4.  5-nucleotidase and azathioprine-related bone-marrow toxicity.

Authors:  P J Kerstens; J N Stolk; L B Hilbrands; L B van de Putte; R A De Abreu; A M Boerbooms
Journal:  Lancet       Date:  1993-11-13       Impact factor: 79.321

5.  Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient.

Authors:  H L McLeod; D R Miller; W E Evans
Journal:  Lancet       Date:  1993-05-01       Impact factor: 79.321

6.  Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?

Authors:  S Zimm; J M Collins; R Riccardi; D O'Neill; P K Narang; B Chabner; D G Poplack
Journal:  N Engl J Med       Date:  1983-04-28       Impact factor: 91.245

7.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.

Authors:  L Lennard; J S Lilleyman; J Van Loon; R M Weinshilboum
Journal:  Lancet       Date:  1990-07-28       Impact factor: 79.321

8.  Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia.

Authors:  J S Lilleyman; L Lennard
Journal:  Lancet       Date:  1994-05-14       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.